According to an article in Fortune, U.S. state Medicaid programs spent $1.3 billion before rebates in 2014 on Gilead Sciences’ new hepatitis C drugs to treat fewer than 2.4 percent of enrollees with the disease, per a U.S. Senate investigation into pricing of the blockbuster medicines. The majority of the 700,000-plus people on Medicaid programs with hep C are still awaiting treatment, the probe found.
“It was always Gilead’s plan to maximize revenue, and affordability and accessibility was an afterthought,” said Senator Ron Wyden, Democrat from Oregon.
Read the full story
Make sure you didn't miss anything: view our monthly news recap
